AbbVie announced a quarterly cash dividend of $1.73 per share, payable on August 14, 2026, to shareholders of record as of July 15, 2026. Since its founding in 2013, AbbVie has increased its dividend by over 330%, reflecting its strong commitment to returning value to shareholders. The company is recognized as a member of the S&P Dividend Aristocrats Index, highlighting its consistent dividend growth for at least 25 years. This dividend declaration underscores AbbVie's financial stability and ongoing focus on rewarding investors.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
